Metsera Raises $275M in IPO to Advance GLP-1 Weight Loss Drug to Phase 3
Metsera priced its initial public offering (IPO) at $18.00 per share, raising approximately $275 million10.
The company offered 15,277,778 shares of common stock and granted underwriters a 30-day option to purchase up to an additional 2,291,666 shares10.
Metsera's lead drug candidate, MET-097i, is a GLP-1 receptor agonist that demonstrated up to 11.3% mean placebo-adjusted weight loss after 12 weeks in a Phase 2a trial13.
The company plans to use the IPO proceeds to fund a Phase 3 trial of MET-097i27.
MET-097i has shown potential for monthly dosing, which could differentiate it from current weekly GLP-1 treatments like Wegovy and Zepbound13.
Metsera's drug pipeline includes other candidates such as MET-233i (an ultra-long acting injectable) and MET-002 (an oral GLP-1RA drug)8.
The company's HALO™ peptide lipidation platform technology enables a longer half-life for its drug candidates, potentially supporting less frequent dosing5.
Metsera's IPO is one of the early biotech public offerings in 2025, potentially signaling a thawing IPO landscape for the sector8.
Sources:
1. https://www.fiercebiotech.com/biotech/metsera-links-glp-1-drug-11-weight-loss-after-12-weeks-teeing-trial-monthly-dosing
2. https://cafepharma.com/boards/threads/metsera-eyes-289m-ipo-to-fund-phase-3-weight-loss-trial.706339/
5. https://www.businesswire.com/news/home/20250106419531/en/Metsera-Announces-Positive-Topline-Phase-2a-Clinical-Data-for-its-Ultra-Long-Acting-GLP-1-Receptor-Agonist-MET-097i
7. https://synapse.patsnap.com/organization/83a9b1fa96368c378d82bd594ad2a722
8. https://www.pharmaceutical-technology.com/news/glp-1ra-developer-metsera-targets-289m-ipo/
10. https://www.globenewswire.com/news-release/2025/01/30/3018515/0/en/Metsera-Announces-Pricing-of-Initial-Public-Offering.html